Table 2 Baseline clinical characteristics of enrolled participants

CD4 count (cells/mm³) Median (IQR), (n =)

217 (69–392), (n = 208)

217 (95–409), (n = 101)

211 (52–381), (n = 107)

CD4 Count < 200 cells/mm³, n (%)

100 (47.2%)

48 (46.2%)

52 (48.2%)

HIV VL

Viral load > 400 copies/mL, n (%)

192 (90.6%)

92 (88.5%)

100 (92.6%)

Viral load ≥ 1000copies/mL, n (%)

183 (86.3%)

89 (85.6%)

94 (87.0%)

Viral Load (log₁₀ copies/mL) Median (IQR)

4.3 (3.7–4.8)

4.2 (3.6–4.7)

4.5 (3.8–4.9)

Duration on ART and self reported adherence

Duration in years on ART Median (IQR), (n =)

6.4 (3.8–8.5), (n = 211)

6.5 (3.9–8.6), (n = 104)

6.4 (3.8–8.4), (n = 107)

Self-reported adherence (95% or higher), n (%)

Total N = 180

134 (74.4%)

61 (67.8%)

73 (81.1%)

ART Regimen

(N = 202)

(N = 101)

(N = 101)

First Line ART Regimen, n (%)

142 (70.2)

69 (68.3)

73 (72.2)

Tenofovir/Lamivudine/Efavirenz

93 (46.0%)

44 (43.6%)

49 (48.5%)

Tenofovir/Lamivudine/Nevirapine

11 (5.5%)

5 (5.0%)

6 (5.9%)

Zidovudine/Lamivudine/Efavirenz

11 (5.5%)

7 (6.9%)

4 (4.0%)

Zidovudine/Lamivudine/Nevirapine

24 (11.9%)

11 (10.9%)

13 (12.9%)

Stavudine/Lamivudine/Efavirenz

1 (0.5%)

1 (1.0%)

0 (0%)

Other

2 (1.0%)

1 (1.0%)

1 (1.0%)

Second Line ART Regimen, n (%)

60 (29.7%)

32 (31.7%)

28 (27.7%)

Tenofovir/Lamivudine/Atazanavir/Ritonavir

33 (16.3%)

17 (16.8%)

16 (15.8%)

Zidovudine/Lamivudine/Atazanavir/Ritonavir

9 (4.5%)

6 (5.9%)

3 (3.0%)

Zidovudine/Lamivudine/Lopinavir/Ritonavir

2 (1.0%)

0 (0%)

2 (2.0%)

Abacavir/Lamivudine/Atazanavir/Ritonavir

9 (4.5%)

4 (4.0%)

5 (5.0%)

Abacavir/Lamivudine/Lopinavir/Ritonavir

7 (4.0%)

5 (5.0%)

2 (2.0%)